Search results for "Mycobacterium ulcerans"

showing 3 items of 3 documents

Fighting mycobacterial infections by antibiotics, phytochemicals and vaccines.

2011

Buruli ulcer is a neglected disease caused by Mycobacterium ulcerans and represents the world's third most common mycobacterial infection. It produces the polyketide toxins, mycolactones A, B, C and D, which induce apoptosis and necrosis. Clinical symptoms are subcutaneous nodules, papules, plaques and ulcerating oedemae, which can enlarge and destroy nerves and blood vessels and even invade bones by lymphatic or haematogenous spread (osteomyelitis). Patients usually do not suffer from pain or systematic inflammation. Surgery is the treatment of choice, although recurrence is common and wide surgical excisions including healthy tissues result in significant morbidity. Antibiotic therapy wit…

Buruli ulcerNecrosismedicine.drug_classImmunologyAntibioticsBacterial ToxinsInflammationApoptosisQuinolonesMicrobiologyNecrosisBacterial ProteinsmedicineVaccines DNAAnimalsHumansBuruli UlcerbiologyMycobacterium ulceransbusiness.industryOsteomyelitisVaccinationNeglected DiseasesChaperonin 60medicine.diseasebiology.organism_classificationRifamycinsAnti-Bacterial AgentsVaccinationInfectious DiseasesLymphatic systemAminoglycosidesMycobacterium ulceransImmunologyBacterial VaccinesMacrolidesmedicine.symptombusinessPhytotherapyMicrobes and infection
researchProduct

Novel M. tuberculosis specific IL-2 ELISpot assay discriminates adult patients with active or latent tuberculosis

2018

Background Tuberculosis (TB) still is a major worldwide health problem, with 10.4 million new cases in 2016. Only 5–15% of people infected with M. tuberculosis develop TB disease while others remain latently infected (LTBI) during their lifetime. Thus, the absence of tests able to distinguish between latent infection and active tuberculosis is one of the major limits of currently available diagnostic tools. Methods A total of 215 patients were included in the study as active TB cases (n = 73), LTBI subjects (n = 88) and healthy persons (n = 54). Peripheral blood mononuclear cells (PBMCs) were isolated from each patient and the LIOSpot® TB anti-human IL-2 ELISpot assay was performed to test …

Bacterial DiseasesMale0301 basic medicinelcsh:MedicineAdult; Aged; Case-Control Studies; Diagnosis Differential; Female; Humans; Immunoassay; Interleukin-2; Latent Tuberculosis; Male; Middle Aged; Mycobacterium tuberculosis; ROC Curve; Species SpecificityFluorescence MicroscopyBiochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)ZoonosesDiagnosisMedicine and Health SciencesBovine TuberculosisEnzyme-Linked Immunoassayslcsh:ScienceImmunoassayMicroscopyMultidisciplinarybiologyLatent tuberculosismedicine.diagnostic_testELISPOTLight MicroscopyMiddle AgedActinobacteriaInfectious DiseasesTuberculosis Diagnosis and ManagementFemaleResearch ArticleAdultTuberculosis030106 microbiologyResearch and Analysis MethodsQuantiFERONDiagnosis DifferentialMycobacterium tuberculosis03 medical and health sciencesSpecies SpecificityAntigenDiagnostic MedicineLatent TuberculosismedicineTuberculosisHumansImmunoassaysAgedBacteriabusiness.industrylcsh:ROrganismsCase-control studyBiology and Life SciencesMycobacterium tuberculosisTropical Diseasesmedicine.diseasebiology.organism_classificationMycobacterium Ulcerans030104 developmental biologyROC CurveCase-Control StudiesImmunoassayDifferentialImmunologyImmunologic TechniquesInterleukin-2lcsh:QbusinessPLOS ONE
researchProduct

Neglected diseases caused by bacterial infections.

2009

Bacterial infections represent a major health problem, especially in third world countries. In endemic regions, large populations of people are greatly affected, but the medical care is very limited. In this review, the neglected diseases buruli ulcer and trachoma are elucidated. Buruli ulcer is caused by Mycobacterium ulcerans which produces an outstanding immunosuppressive toxin mycolactone that induces an ulcerative, necrotic skin disease. Until today, only the combination of rifampin/streptomycin is used to treat buruli ulcer. However, this therapy is ineffective and expensive. Here, we report new findings that suggest pharmaceutical formulations such as rifapentine, in combination with…

Buruli ulcerChlamydia trachomatismedicine.disease_causeAzithromycinBiochemistryMicrobiologychemistry.chemical_compoundRare DiseasesPersonal hygieneClarithromycinDrug DiscoverymedicineAnimalsHumansMycolactoneBuruli UlcerPharmacologyTrachomabiologyMycobacterium ulceransbusiness.industryOrganic ChemistryVaccinationmedicine.diseasebiology.organism_classificationAnti-Bacterial AgentsTrachomachemistryMycobacterium ulceransImmunologyMolecular MedicineChlamydia trachomatisbusinessmedicine.drugCurrent medicinal chemistry
researchProduct